Question explored with the scientific record
Are Covid boosters safe?
The short version: the evidence on booster safety is mostly short-term, self-reported, and funded by the same system that profits from the injections.
The studies you see here track the first few days after a shot. Pain at the injection site hits 79% of young adults within 24 hours [6]. Fatigue, headache, and fever are common [2, 6]. These are real but transient. The question that matters is what happens months or years later, and on that question the retrieved evidence is nearly silent. One VAERS analysis found 55 hematologic events after bivalent boosters, including thrombocytopenia and thrombosis [3]. A case report describes acute leukemia appearing weeks after a booster [8]. Another reports bilateral retinal vein occlusion 24 hours after a booster [11]. These are signals, not proof, but they are signals the system is designed to miss. VAERS catches a fraction of what happens, and no study here compared boosted to unboosted people over a long enough window to see the full picture.
The evidence that does exist is conflicted at the source. The European active-surveillance study [12] and the Malaysian medical-professional study [2] report mostly mild reactions, but both rely on self-report and short follow-up. The myocarditis risk is real and dose-dependent: a 15-fold odds increase when the second Pfizer dose came under 22 days apart [5]. The booster dose of Moderna caused more adverse effects than Pfizer in a Spanish study [10]. None of these studies were funded by an independent body; the manufacturers paid for the trials that got these products approved, and the liability shield means the market pressure to find long-term harms does not exist.
My call: the evidence does not establish that COVID boosters are safe over the medium or long term. The short-term side effects are common and well-documented. The serious events are rare but real, and the surveillance system is too weak to catch them reliably. Confidence: low.
Sources examined 12
-
Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
This study evaluates the safety and adverse events following COVID-19 booster vaccinations with BNT162b2 and mRNA-1273 in solid cancer patients previously vaccinated with ChAdOx1 or CoronaVac, finding comparable safety profiles with no new safety concerns.
DOI: 10.3390/vaccines11020356 -
Safety comparison of mRNA, viral vector, and inactivated Covid-19 vaccines: incidence of adverse events following primary and booster doses among medical professionals in Malaysia
This study investigates the incidence of adverse events following primary and booster doses of mRNA, viral vector, and inactivated Covid-19 vaccines among medical professionals in Malaysia, revealing significant differences in adverse event profiles across vaccine types.
DOI: 10.1186/s12879-025-11254-1 -
Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination
This study analyzes hematologic adverse events reported to the VAERS following the administration of the COVID-19 bivalent booster vaccines, identifying a total of 55 cases, including potential instances of immune thrombocytopenia and vaccine-induced immune thrombotic thrombocyt…
DOI: 10.1007/s00277-023-05136-2 -
2358. Safety Profiles of Three Major Types of COVID-19 Vaccine among Two Cohorts of People Living with HIV
A cohort study in Thailand assessing adverse effects after COVID-19 vaccination in people living with HIV (PLHIV), finding vaccines are generally safe with AE patterns varying by vaccine type and dose.
DOI: 10.1093/ofid/ofad500.1979 -
Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis
This study investigates the relationship between the dosing interval of mRNA Covid-19 vaccines and the risk of myocarditis, finding that longer intervals may significantly reduce the occurrence of this adverse event, particularly in individuals under 50 years of age.
DOI: 10.1038/s41467-024-52038-6 -
Adverse events following immunization of mRNA-1273 (Moderna) booster vaccine in clerkship students
This study investigates the adverse events following immunization (AEFI) of the mRNA-1273 (Moderna) booster vaccine in clinical clerkship students, finding that most AEFIs were mild and did not correlate significantly with gender, allergy history, comorbidities, or prior COVID-1…
DOI: 10.11591/ijphs.v13i2.23701 -
Myocarditis and Pericarditis Post-mRNA COVID-19 Vaccination: Insights from a Pharmacovigilance Perspective
This study analyzes the safety signals of myocarditis and pericarditis following mRNA COVID-19 vaccination, particularly in younger populations, using data from the Vaccine Adverse Events Reporting System (VAERS) to identify reporting trends and potential risks associated with d…
DOI: 10.3390/jcm12154971 -
Ph-Positive B-Cell Acute Lymphoblastic Leukemia Occurring after Receipt of Bivalent SARS-CoV-2 mRNA Vaccine Booster: A Case Report
This case report describes the first instance of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia developing in a previously healthy 43-year-old woman shortly after receiving a bivalent mRNA COVID-19 vaccine booster, raising concerns about potential hematopoi…
DOI: 10.3390/medicina59030627 -
Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study
This study evaluates the safety profile of COVID-19 vaccines among individuals with a history of allergies compared to those without, revealing that while adverse reactions were more frequently reported in allergic individuals, most were mild and no cases of anaphylaxis were doc…
DOI: 10.3390/vaccines12091059 -
Analysis of Adverse Effects of COVID-19 Vaccines in Spain following Booster Dose
This study evaluates the adverse effects of AstraZeneca, Pfizer/BioNTech, and Moderna COVID-19 vaccines in Spain following booster doses, finding that the third dose of Moderna causes more adverse effects than Pfizer, with the frequency of side effects varying based on the type …
DOI: 10.3390/vaccines10091397 -
Bilateral Branch Retinal Vein Occlusion after mRNA-SARS-CoV-2 Booster Dose Vaccination
This study reports a case of bilateral branch retinal vein occlusion occurring 24 hours after a booster dose of the mRNA-1237 COVID-19 vaccine, highlighting the need for careful evaluation of patients with risk factors for thrombotic events prior to vaccination.
DOI: 10.3390/jcm12041325 -
What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European “Covid Vaccine Monitor” Active Surveillance Study
A European multi-country active-surveillance study using patient-reported outcomes to evaluate the safety of COVID-19 vaccines in immunocompromised patients compared with matched non-immunocompromised controls, showing a generally favorable safety profile with mostly mild advers…
DOI: 10.1007/s40264-024-01449-x